C12N 2810/405
Vectors comprising rgd peptide
Official title: Vectors comprising RGD peptide
C12N2810/405 (Vectors comprising rgd peptide) appears on 52 US grants and 84 published applications in this corpus.
Search patents in C12N- Granted patents
- 52
- Published applications
- 84
- Assignees
- 52
- Inventors
- 159
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 4 | 0 |
| 1999 | 2 | 0 |
| 2000 | 4 | 0 |
| 2001 | 2 | 1 |
| 2002 | 4 | 8 |
| 2003 | 2 | 12 |
| 2004 | 2 | 4 |
| 2005 | 3 | 6 |
| 2006 | 3 | 8 |
| 2007 | 1 | 3 |
| 2008 | 2 | 2 |
| 2009 | 0 | 4 |
| 2010 | 1 | 6 |
| 2011 | 1 | 1 |
| 2012 | 2 | 4 |
| 2013 | 2 | 2 |
| 2014 | 0 | 1 |
| 2015 | 1 | 0 |
| 2016 | 0 | 0 |
| 2017 | 3 | 1 |
| 2018 | 0 | 4 |
| 2019 | 2 | 1 |
| 2020 | 2 | 1 |
| 2021 | 0 | 1 |
| 2022 | 1 | 3 |
| 2023 | 2 | 2 |
| 2024 | 1 | 2 |
| 2025 | 3 | 3 |
| 2026 | 1 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-tumor composition12 May 2026US 12,622,936 B2Genemedicine Co., Ltd.
- Adenosomes7 Oct 2025US 12,435,110 B2Erasmus University Medical Center Rotterdam
- Engineered muscle targeting compositions9 Sep 2025US 12,410,447 B2Massachusetts Institute of Technology
- Phagemid vector17 Jun 2025US 12,331,308 B2Imperial College Innovations Limited
- Engineered muscle targeting compositions5 Mar 2024US 11,920,150 B2Massachusetts Institute of Technology
- Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same23 Jul 2026US 2026/0207773 A1The Trustees of the University of Pennsylvania
- Liver detargeted capsids18 Jun 2026US 2026/0167991 A1Kate Therapeutics, Inc.
- Engineered muscle targeting compositions7 May 2026US 2026/0125706 A1Massachusetts Institute of Technology
- Engineered muscle targeting compositions12 Mar 2026US 2026/0071236 A1Massachusetts Institute of Technology
- Compositions and methods for muscle disorders7 Aug 2025US 2025/0249052 A1Kate Therapeutics, Inc.
Most cited
By later US patents
- Virus vectors and methods of making and administering the same197US 7,172,893 B2The University of North Carolina at Chapel Hill · 2007
- Recombinant parvovirus vectors and method of making167US 6,491,907 B1The University of North Carolina at Chapel Hill · 2002
- Targeting adenovirus with use of constrained peptide motifs158US 5,846,782 AGenVec, Inc. · 1998
- Penton base protein and methods of using same136US 5,559,099 AGenVec, Inc. · 1996
- AAV2 vectors and methods109US 6,962,815 B2Children's Hopital Inc. · 2005